SIREN : 421803115
CLINISYS FRANCE is a French company founded 27 years ago, specialized in the sector Edition de logiciels applicatifs. Based in PARIS (75013), this company of category PME shows in 2024 a revenue of 17.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 169 999 € | 15 574 533 € | 14 839 048 € | 13 073 863 € | 10 641 304 € | 7 989 176 € | 9 560 716 € | 6 777 614 € | 5 095 553 € |
| Net income | 306 548 € | 349 736 € | 323 549 € | 302 310 € | 446 163 € | 261 014 € | 372 877 € | 692 541 € | 670 650 € |
| EBITDA | 374 867 € | 348 850 € | 317 050 € | 278 060 € | 539 271 € | 339 194 € | 390 941 € | 1 090 016 € | 974 541 € |
| Net margin | 1.8% | 2.2% | 2.2% | 2.3% | 4.2% | 3.3% | 3.9% | 10.2% | 13.2% |
In 2024, CLINISYS FRANCE achieves revenue of 17.2 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +16.4%. Vs 2023, growth of +10% (15.6 M€ -> 17.2 M€). After deducting consumption (0 €), gross margin stands at 17.2 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 375 k€, representing 2.2% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 307 k€, i.e. 1.8% of revenue. This profit can be retained or distributed to shareholders.
17 169 999 €
17 169 999 €
374 867 €
535 191 €
306 548 €
2.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory. Cash flow represents 1.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.0%
28.469%
1.441%
0.0
69.9%
In 2024, the debt ratio of CLINISYS FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of CLINISYS FRANCE (28.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of CLINISYS FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 162.41. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 3.1x. Financial charges are adequately covered by operations.
162.409
3.107
In 2024, the liquidity ratio of CLINISYS FRANCE (162.41) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of CLINISYS FRANCE (3.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 186 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 216 days. Favorable situation: supplier credit is longer than customer credit by 30 days. Overall, WCR represents 121 days of revenue, i.e. 5.8 M€ to permanently finance. Over 2016-2024, WCR increased by +729%, requiring additional financing.
5 763 797 €
186 j
216 j
0 j
121 j
Based on 103 transactions of similar company sales (all years), the value of CLINISYS FRANCE is estimated at 1 538 175 € (range 653 683€ - 3 655 841€). With an EBITDA of 374 867€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.25x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CLINISYS FRANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Edition de logiciels applicatifs
The revenue of CLINISYS FRANCE in 2024 is 17.2 M€.
Yes, CLINISYS FRANCE generated a net profit of 307 k€ in 2024.
The headquarters of CLINISYS FRANCE is located in PARIS (75013), in the department Paris.
The tax return of CLINISYS FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CLINISYS FRANCE operates in the sector Edition de logiciels applicatifs (NAF code 58.29C). See the 'Sector positioning' section above to compare the company with its competitors.